10.1038/sj.onc.1209080
10.1038/sj.onc.1209080 · doi-reference
The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer
10.1093/nar/gkaa653 · doi-reference
A novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation
10.1016/j.tranon.2017.07.008 · doi-reference
10.1016/j.stem.2017.11.016
10.1016/j.stem.2017.11.016 · doi-reference
10.1039/c8fo02004c
10.1039/c8fo02004c · doi-reference
Mining for METTL3 inhibitors to suppress cancer
10.1038/s41594-021-00606-5 · doi-reference
10.1038/s41586-021-03536-w
10.1038/s41586-021-03536-w · doi-reference
Discovery of two novel ALKBH5 selective inhibitors that exhibit uncompetitive or competitive type and suppress the growth activity of glioblastoma multiforme
10.1111/cbdd.14051 · doi-reference
10.1002/med.21565
10.1002/med.21565 · doi-reference
Rational design of novel anticancer small-molecule RNA m6A demethylase ALKBH5 inhibitors
10.1021/acsomega.1c01289 · doi-reference
10.1016/j.ccell.2019.03.006
10.1016/j.ccell.2019.03.006 · doi-reference
10.1016/j.celrep.2017.02.059
10.1016/j.celrep.2017.02.059 · doi-reference
Identification of Clausine E as an inhibitor of fat mass and obesity-associated protein (FTO) demethylase activity
10.1002/jmr.2800 · doi-reference
10.1016/j.cmet.2021.04.001
10.1016/j.cmet.2021.04.001 · doi-reference
10.1016/j.cell.2017.11.031
10.1016/j.cell.2017.11.031 · doi-reference
10.1021/acs.jmedchem.5b00702
10.1021/acs.jmedchem.5b00702 · doi-reference
10.1021/acs.biochem.6b00023
10.1021/acs.biochem.6b00023 · doi-reference
10.1021/ja3064149
10.1021/ja3064149 · doi-reference
10.1093/nar/gku1276
10.1093/nar/gku1276 · doi-reference
Fluorescein derivatives as bifunctional molecules for the simultaneous inhibiting and labeling of FTO protein
10.1021/jacs.5b06690 · doi-reference
10.1371/journal.pone.0159072
10.1371/journal.pone.0159072 · doi-reference
10.1016/j.omtn.2020.06.001
10.1016/j.omtn.2020.06.001 · doi-reference
Construction of an m6A-related lncRNA pair prognostic signature and prediction of the immune landscape in head and neck squamous cell carcinoma
10.1002/jcla.24113 · doi-reference
Immune infiltrates of m(6)A RNA methylation-related lncRNAs and identification of PD-L1 in patients with primary head and neck squamous cell carcinoma
10.3389/fcell.2021.672248 · doi-reference
10.1021/acs.biomac.1c01571
10.1021/acs.biomac.1c01571 · doi-reference
m(6)A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
10.1038/s41467-019-10669-0 · doi-reference
10.1002/smll.202106558
10.1002/smll.202106558 · doi-reference
10.1016/j.ccell.2020.04.017
10.1016/j.ccell.2020.04.017 · doi-reference
m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in acute myeloid leukemia
10.3389/fimmu.2021.789914 · doi-reference
Characterization of the m6A-associated tumor immune microenvironment in prostate cancer to aid immunotherapy
10.3389/fimmu.2021.735170 · doi-reference
Significance of N6-methyladenosine RNA methylation regulators in immune infiltrates of ovarian cancer
10.3389/fgene.2021.671179 · doi-reference
Classification and immune invasion analysis of breast cancer based on m6A genes
10.21037/atm-21-3404 · doi-reference
10.1038/s41417-020-00208-1
10.1038/s41417-020-00208-1 · doi-reference
The expression of m(6)A regulators correlated with the immune microenvironment plays an important role in the prognosis of pancreatic ductal adenocarcinoma
10.21037/gs-21-859 · doi-reference
10.1016/j.ebiom.2021.103271
10.1016/j.ebiom.2021.103271 · doi-reference
10.18632/aging.203939
10.18632/aging.203939 · doi-reference
CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via m(6)A modification in hepatocellular carcinoma
10.1016/j.omto.2022.02.021 · doi-reference
Analysis of m6A-related lncRNAs for prognosis value and response to immune checkpoint inhibitors therapy in hepatocellular carcinoma
10.2147/cmar.s322179 · doi-reference
Identification of an m6A-related signature as biomarker for hepatocellular carcinoma prognosis and correlates with sorafenib and anti-PD-1 immunotherapy treatment response
10.1155/2021/5576683 · doi-reference
m(6) A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy
10.15252/embj.2020104514 · doi-reference
